03/12/2018
Marie Skłodowska-Curie Actions

I-Direct (ESR 1): "Development and preclinical validation of tumour-selective PD-1/PD-L1 immunotherapeutics and drug delivery systems"

This job offer has expired


  • ORGANISATION/COMPANY
    UMCG
  • RESEARCH FIELD
    Biological sciencesOther
    ChemistryOther
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    28/02/2019 00:00 - Europe/Brussels
  • LOCATION
    Netherlands › Groningen
    Czech Republic › Praha
  • TYPE OF CONTRACT
    Temporary
  • JOB STATUS
    Full-time
  • HOURS PER WEEK
    40
  • OFFER STARTING DATE
    01/04/2019
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • REFERENCE NUMBER
    I-Direct 813871
  • MARIE CURIE GRANT AGREEMENT NUMBER
    813871

Keywords: checkpoint targeting, bispecific antibody, nanoparticles, surface modification, drug-delivery

 

1st Hosting institution: Location: UMCG, Groningen, Netherlands; Duration: 18 months

2nd Hosting institution: Location: InoCure, Prag, Czech Republic; Duration: 18 months

 

PhD-student position (3 years):

This PhD student position offers an exciting and innovative research project that aims to further develop the targeting of the PD-1/PD-L1 immune checkpoint for cancer immunotherapy. In brief, a novel bispecific antibody-based approach that selectively removes this important checkpoint at the site of the cancer will be developed. Further, the immunotherapeutic will be formulated using nanotechnology to ensure timely and tumor-localized release of bioactive drug. This approach will be tested in in-house developed model systems for tumor-selective binding and functional immunomodulatory activity.

The PhD candidate will be working as part of an international consortium on their search for an immunotherapeutic approach to cancer treatment and will start their 3 year research project at the University Medical Center Groningen (UMCG) / Netherlands, one of the leading academic centers of the Netherlands, for another 18 months. At the UMCG, new PD-1 checkpoint targeting immunotherapeutic will be developed and preclinically evaluated. After 18 months, the candidate will continue in Prague / Czech Republic at the nanobiotechnology company Inocure SRO. Inocure is a leading company in drug formulation and in in vitro modelling and the candidate will exploit this expertise for further development of PD-1 checkpoint immunotherapeutics. With this project, the candidate will acquire experience in both industrial and academic research. This research project will end with a PhD thesis defense at the University of Groningen.

This project is part of a collaborative training network of 10 closely related projects in which PhD students will benefit from networking opportunities. This includes a multidisciplinary training programme with network-wide training events that will be provided to the candidates. Herewith, the PhD project will provide the candidate a unique opportunity to obtain knowledge/expertise on important facets of both academia and industry.

 

SEE THE OTHER 9 PhD POSITIONS AND WORK LOCATIONS OF I-DIRECT:

10 position(s) available at various locations (2 locations for each ESR, 18 months each)

ESR2: Cancer immunomodulation upon tumour-selective targeting of innate immune checkpoints

Netherlands/Germany

ESR3: Development, label free bioanalysis and preclinical validation of Adenosine-2A-Receptor (A2AR)-targeting bispecific antibodies

Germany/Netherlands

ESR4: Development of stimuli-sensitive particles for tumour-selective targeting of TIM-3/Galectin-9

Germany/Netherlands

ESR5: Targeted inhibition of novel immune checkpoints

Netherlands/Germany

ESR6: Development and characterization of antibody fusion proteins with tumour-restricted FcgR-independent co-stimulatory activity by targeting CD70

Germany/Czech Republic

ESR7: Development and characterization of antibody fusion proteins with tumour-restricted FcgR-independent co-stimulatory activity by targeting PD-L1

Germany/Czech Republic

ESR8: Development of stimuli-sensitive nanoparticles and in vivo evaluation of immune-stimulatory TNFSF ligand fusion proteins with FAP-restricted activity

Czech Republic/Germany

ESR9: Development of immunomodulatory Dual Signalling Proteins (DSPs) for cancer immunotherapy

Israel/The Netherlands

ESR10: Nanoparticles for targeted delivery to tumours

Czech Republic/The Netherlands

Web site for additional job details

Required Research Experiences

  • RESEARCH FIELD
    Biological sciencesOther
  • YEARS OF RESEARCH EXPERIENCE
    1 - 4
  • RESEARCH FIELD
    Chemistry
  • YEARS OF RESEARCH EXPERIENCE
    1 - 4

Offer Requirements

  • REQUIRED EDUCATION LEVEL
    Biological sciences: Master Degree or equivalent
    Chemistry: Master Degree or equivalent
  • REQUIRED LANGUAGES
    ENGLISH: Excellent

Skills/Qualifications

Key Responsibilities:

  • Preparation of tumour-targeted bsAbs & immunocytokines
  • Nanoparticle-based drug-delivery formulation
  • Primary patient-derived cell culturing
  • Development of 3D model of tumor micro-environment
  • Various encapsulation and surface modification activities
  • Optimization of the in vitro test conditions for a realistic simulation of the in vivo conditions
  • Management, presentation and publication of research data

Specific Requirements

  • Candidate is in the first four years of his/her research career and does not have a doctoral degree
  • Residence duration in the Netherlands does not exceed 12 months in total within the last 3 years
  • MSc in biology, biochemistry, biotechnology, engineering or related
  • Collaboration skills, demonstrating agility and initiative. Ability to communicate effectively in English

Work location(s)
1 position(s) available at
UMCG
Netherlands
Groningen
9713 GZ
HANZEPLEIN 1
1 position(s) available at
InoCure
Czech Republic
Praha
11000
KLIMENTSKA 1652/36

EURAXESS offer ID: 360232

Disclaimer:

The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.

 

Please contact support@euraxess.org if you wish to download all jobs in XML.